High doses of ketamine can lead to persistent psychosis, especially in individuals with existing substance use disorders. This raises significant concerns about access to ketamine for treating depression, as many programs exclude those with addiction issues. Innovative strategies, such as activating drug memories during treatment, aim to mitigate these risks while ensuring ketamine is administered safely in clinical settings.
